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Multiple sclerosis (MS) is the most common autoimmune disorder affecting 
the central nervous system. Epstein-Barr virus (EBV) is a causative agent for infectious 
mononucleosis (IM) that is associated with MS pathogenesis. However, the exact 
mechanism by which EBV, specifically in IM, increases the risk for MS remains 
unknown. EBV immortalizes primary B lymphocytes in vitro and causes excessive B 
lymphocyte proliferation in IM in vivo. In asymptomatic carriers, EBV-infected B 
lymphocytes still proliferate to certain degrees, the process of which is tightly 
controlled by the host immune systems. Experimental autoimmune encephalomyelitis 
(EAE) mimics key features of MS in humans and is a well-established rodent model for 
human MS. We have found that xenografts of EBV-immortalized B lymphocytes, 
which partially resemble the hyperproliferation of EBV-infected cells in IM, exacerbate 
autoimmune responses in myelin oligodendrocyte glycoprotein-induced EAE in 
C57BL/6 mice. After remission, an additional challenge with EBV-immortalized cells 
induces a relapse in EAE. Moreover, xenografts with EBV-immortalized cells tighten 
the integrity of blood brain barrier (BBB) in thalamus and hypothalamus areas of the 
mouse brains. Genomic sequences of prokaryotic 16S rRNA presented in feces reveal 
that EBV-immortalized cells significantly change the diversities of microbial 
populations. Our data collectively suggest that EBV-mediated proliferation of B 
lymphocytes may be a risk factor for the exacerbation of MS, which are associated with 
gut microbiome changes and BBB modulations. Furthermore, multiple xenografts of 
EBV-immortalized cells into in C57BL/6 mice could sever as a useful model for human 
relapsing-remitting MS with predictable severity and timing. 
 













• Mimic IM with EBV-immortalized cells enhances EAE in C57BL/6 mice  
• Changes in BBB and microbiome are associated with the enhancement  
• Multiple exposure of EBV-immortalized cells could sever as a model for human 
relapsing-remitting MS with predictable severity and timing 
Key words: Epstein Barr virus, multiple sclerosis, experimental autoimmune 
encephalomyelitis, gut microbiome, magnetic resonance imaging 
1. Introduction 
Multiple sclerosis (MS) is the most common autoimmune disorder affecting 
the central nervous system. Pathogenically, the insulating myelinations of nerve cells in 
the brain and spinal cord are damaged. Damaged myelin disrupts neuronal 
communication, resulting in a range of signs and symptoms, including physical, mental, 
and sometimes psychiatric problems 1. Although the clinical presentation and course of 
the disease are highly variable, several MS types are recognized, including relapsing-
remitting MS (RRMS) and secondary progressive MS (SPMS) 2,3. Despite decades of 
research, the causes of MS, are not yet well understood. 
Epstein–Barr virus (EBV) is a member of human herpesvirus family that is 
associated with several human cancers 4,5. EBV mainly targets B lymphocytes and 
epithelial cells. EBV has two major infection stages: lytic and latent infections. The 
lytic replication cycle results in the production of infectious virions. In latency, only a 
portion of EBV's genes are expressed. In vitro, EBV infects and immortalizes B 
lymphocytes efficiently and generate continuously growing lymphoblastoid cell lines 
(LCL) and establish a type III latency 4,6. In most cases EBV infection is asymptomatic 












but some individuals develop self-limiting infectious mononucleosis (IM), whose 
symptoms are initiated by overproliferation of EBV-infected B lymphocytes, majority 
of which are type III latency 4,6-9.  
Several lines of evidence strongly support the notion that EBV infection is a 
risk factor for MS pathogenesis: MS patients have universal EBV seropositivity, higher 
EBV antibody levels in the blood and higher concentrations of virions in the saliva 10-12. 
Moreover, MS patients tend to have reduced EBV-specific CD8+ T-cell immunity, but 
increased EBV-positive B lymphocytes and plasma cells in the brains. Furthermore, 
spontaneous EBV-induced immortalization of peripheral blood B lymphocytes from 
MS patients are increased 13-15. 
While the association between MS and EBV, particular in IM, is fairly strong, 
the exact mechanism by which EBV increases the risk of MS remains unknown. 
Unfortunately, EBV does not infect rodent cells and there is no murine EBV equivalent 
discovered yet. Therefore, there is a need for generating a rodent MS model 
incorporating EBV.  
Experimental autoimmune encephalomyelitis (EAE) is a well-characterized 
animal model to study the etiology and pathogenesis of MS 16,17. By mimicking 
hyperproliferation of B-lymphocytes in IM in vivo, we have discovered that xenografts 
of EBV-immortalized B lymphocytes exacerbate autoimmune responses in a rodent 
EAE model. Also, the phenotype of EAE is associated with significant gut microbiota 
changes and tightening of blood brain barrier (BBB) in certain areas of the mouse 
brains. The results suggest that overproliferation of EBV-infected B lymphocytes may 












be a factor for MS development. Moreover, a novel model for RRMS with predictable 
severity may be generated.  
2. Methods 
2.1. Active Induction of EAE and Cell lines 
C57BL/6J and APP-null (app−/−; B6.129S7-Apptm1Dbo/J) mice were purchased from 
Jackson Laboratories. All mice were bred and housed at the American Association for 
Accreditation of Laboratory Animal Care-accredited facility under specific-pathogen-
free conditions. C57BL/6 mice are a common strain for modelling EAE, while the 
amyloid precursor protein (APP)-null strain was derived from C57BL/6 but is more 
sensitive for EAE induction 18. All experimental protocols were approved by the 
Institutional Animal Care and Use Committee (IACUC) and Institutional Biosafety 
Committee (IBC) of the University of Nebraska–Lincoln and followed federal guideline. 
All research staffs were trained in animal care or handling. Cells were washed with PBS 
and desired numbers in PBS were injected into mice in an intraperitoneal (i.p.) manner. 
Myelin oligodendrocyte glycoprotein peptide (MOG35-55) were synthesized from 
Novopep Inc in large quantities. An emulsion containing 100 μg of MOG peptide in 
complete Freund’s adjuvant (CFA; Mycobacterium tuberculosis H37Ra, 4 mg/mL) was 
injected subcutaneously on either hind flank as two injections. In addition, 200 ng of 
pertussis toxin was injected intraperitoneally (ip) on the same day as MOG-CFA, and 
another dose was administered after 48 h following standard protocol 19. Clinical EAE 
symptoms in mice were evaluated daily with: 0.5=partially limp tail,1=paralyzed tail, 
2=paralyzed tail and hind limb paresis, 2.5=paralyzed tail and one hind limb, 3=both 
hind limbs paralyzed, 3.5=both hind limbs paralyzed, fore limbs partially paralyzed, 












4=complete hind and fore limb paralysis, 5=moribund 20. The severity of EAE was 
scored on daily basis by two researchers, and occasionally a third researcher was used 
for calibrations. All animal welfare considerations were taken, including efforts to 
minimize suffering and distress. When a weight loss of 10-15% within a few days or 
EAE scores 4 or above, those mice were euthanized immediately. The whole 
experiments took 2-3 months to finish.  
EBV-immortalized B lymphocytes from a SPMS patient (MS-LCL) were 
obtained from Multiple Sclerosis Genetic Susceptibility Project at University of 
California, San Francisco (UCSF). The immortalized cells were amplified and passaged 
in tissue culture system constantly and exhibited EBV type III latency based on EBV 
gene expression and morphology (data not sown). MS-Human EBV-positive Sav I and 
Sav III cell lines were gifts from Dr. Jeff Sample. The two lines are isogenic with 
different EBV-latencies (Sav I: type I latency; and SavIII, type III latency). The cells 
were grown and maintained in Roswell Park Memorial Institute (RPMI) 1640 medium 
(GIBCO Cat#: 11875135) containing 10% fetal bovine serum (FBS) (Atlanta 
Biologicals, cat#: S11150) and 1X penicillin-streptomycin (PS) (Thermo Fisher 
Scientific Cat#: 15140163) in a humidified chamber with 5% CO2 at 37°C.  
2.2. Western Blot Analysis with Enhanced Chemiluminescence (ECL)  
Cells were collected and dissolved in 2x SDS loading buffer. Separation of proteins 
on SDS-PAGE was carried out following the standard protocol. After the proteins 
were transferred to a nitrocellulose (BIO-RAD, Cat# 1620112), or immobilon 
membrane (Millipore, IPVH00010), the membranes were placed with Ponceau S 
stain solution (0.5% Ponceau S in 1% acetic acid) for 30 seconds to 1 minute. 












Several changes of water for 30 seconds to 1 minute each were used for destaining 
the membranes. Stop the destaining as soon as the background got slight pink. The 
intensity of the bands on the membrane could be used for the rough quantifications 
of proteins on PVDF or nitrocellulose membranes 21. The membrane was then 
blocked with 5% nonfat dry milk in TBST (50 mM Tris-HCl pH 7.5, 200 mM NaCl, 
0.05% Tween-20) at room temperature for 30 minutes. It was washed briefly with 
TBST, and incubated with individual mouse serum in 1% milk in TBST for 1 hour at 
room temperature, or overnight at 4 °C. The mouse plasmas were obtained from 
participating mice after euthanization. Briefly, whole blood was collected and put 
into EDTA-treated tubes. Cells were removed by centrifugation for 15 minutes at 
1,500x g. The resulting supernatant was designated plasma. After washing the 
membrane with TBST three times (10 minutes each), it was incubated with the 
secondary antibody at room temperature for 1 h. The goat anti-mouse IgG-HRP 
antibody was purchased from Santa Cruz Biotechnology (sc-2005). The membrane 
was then washed three times with TBST, treated with ECL detection reagents, and 
exposed to BlueBlotTMHS film from Life Science Products (XR-0810-100).  
2.3. Microbial DNA Extraction  
To collect the fecal samples, mice were placed in an empty sterile cage for 5–10 min 
and freshly dropped fecal pellets were collected aseptically into sterile tubes. To obtain 
the cecum contents, mice were euthanized and sacrificed. Ceca were immediately 
collected and stored at -80°C until use. DNA was extracted from fecal samples using 
the Omega Mag-Bind® Soil DNA 96 Kit (Omega Bio-tek Inc., Norcross, GA) 
according to the manufacturer’s protocol. Isolated DNA was stored at -20°C until used 
for bacterial community analysis. The bacterial community was evaluated using the V4 












region of the 16S rDNA. Briefly, the V4 region of the 16S rDNA gene was amplified 
using barcoded universal primers and was multiplexed and sequenced using the MiSeq 
Illumina platform using 250bp paired end sequencing using the V2 500 cycle reagent 
kits. Library preparation PCR contained, 0.75 Units of Terra PCR Direct Polymerase 
Mix, 1X Terra PCR Direct Buffer, 0.4 uM indexed primers, and 10 – 25 ng of DNA. 
Cycling conditions included, initial denaturation of 98 °C for 2 min, followed by 25 
cycles of 98°C for 10 s, 55°C for 30 s, and 68°C for 30 s; and a final extension of 68 °C 
for 4 min. The resulting PCR amplicons were normalized using the Charm Biotech 
Normalization Kit (Charm Biotech, San Diego, CA) following the manufacturer’s 
protocol. Normalized libraries were pooled and were further purified using 
NucleoSpin® Gel and PCR Clean-up (Macherey-Nagal Inc, Bethlehem, PA). The 
resulting libraries were subjected to 250bp pair end sequencing using the Illumina 
MiSeq System (Illumina, San Diego, CA) using the V2 500 cycle sequencing kit as 
described by the manufacturer.  
2.4. Data Processing pipeline 
The DADA2 v1.10.1 pipeline was used to identify bacterial community changes as 
described previously 22. In short, low-quality reads with a Q score of ≥25 were removed 
and the reads were trimmed to a consistent length of 200 bp. Error rates were estimated 
to distinguish rare variants from sequencing or base calling errors and contigs were 
assembled using the forward and reverse reads to generate contigs for the V4 region. 
Furthermore, quality filtering was performed to remove sequences with ambiguous 
bases, incorrect contig length, or assembly. Taxonomy was assigned using SILVA 
reference alignment database v132 and a phylogenetic tree was generated in MOTHUR 
(v.1.42.1). The resulting normalized (DeSeq2) ASV table was used for Principal 












Coordinate Analysis (PCoA) using a weighted unifrac matrix within R by using the 
package ggplot2 (Wickham 2009). The weighted Unifrac distance matrix was used to 
perform multivariate analysis of variance (PERMANOVA) within the R package 
vegan.  
2.5. Magnetic Resonance Imaging (MRI) 
MRI was performed on a 7 Tesla small animal scanner (Bruker PharmaScan 70/16, 
Billerica, MA) operated using ParaVison 6.01. A Bruker made mouse head quadrature 
RF coil was used for signal transmitting and receiving. Mice were anesthetized by 
inhalation of 1-2% isoflurane in oxygen during scanning, and respiration and body 
temperature were monitored (Model 1025 Monitoring & Gating System, Small Animal 
Instruments, Inc., Stony Brook, NY). T2-weighted coronal brain images were first 
obtained using Rapid Acquisition with Relaxation Enhancement (RARE) as an 
anatomical reference (TR/TE = 4200/48 ms, FOV = 20 x 20 mm2, matrix size = 256 x 
192, 21 slices, slice thickness = 0.5 mm, and averaging = 2). T1-weighted and T1 
mapping scans were performed before and after intraperitoneal (i.p.) administration of 
gadolinium (MultiHance, Bracco Imaging) at 0.2 mM/kg. Modified driven equilibrium 
Fourier transform (MDEFT) was used for T1-weighted imaging with TR/TE/TI = 
2600/2.2/950 ms, flip angle = 15o, FOV = 20 x 20 mm2, matrix size = 256 x 256, 15 
slices and slice thickness = 0.5 mm. T1 mapping data acquired using variable TR RARE 
(RAREVTR) with 6 TRs from 9 to 0.4 s. Other parameters included TE = 8 ms, FOV = 
20 x 20 mm2, matrix size = 96 x 128, 15 slices with slice thickness = 0.5 mm. T1 maps 
were calculated using an in-house developed fitting program written in IDL. T1 values 
on somatosensory cortex, hippocampus, striatum, thalamus and hypothalamus using 
region-of-interest (ROI) analysis. 












2.6. Statistical analysis 
Mann-Whitney U one-tailed test analyses were done with the use of Mann-Whitney U 
Test Calculator (https://www.socscistatistics.com/tests/mannwhitney/default2.aspx). 
General statistical analyses were performed by functions implemented in Microsoft 
Excel Program. Two group comparisons were done with Student’s two-tailed unpaired 
t-test. The p values of < 0.05 were considered statistically significant and highly 
significant if p < 0.01 in all analyses. 
3. Results 
3.1. EBV-immortalized cells exacerbate EAE responses in mice During IM, EBV-
infected B lymphocytes proliferate excessively and elicit strong immune responses, as 
they are viewed as foreign by the human immune system 9,23,24. One of immune 
responses is the induction of heterophile antibodies. The well-established monospot test 
for IM diagnosis is based on the detections of heterophile antibodies 25. There are 
several types of EBV-infected cell types and latency III latency cells are one of the 
predominant ones during IM 8,26. Healthy EBV-carriers may occasionally have 
expansions of EBV-infected B lymphocytes and those cells are quickly removed by the 
EBV-specific immune cells 6,26-29. The occasional expansions of EBV-infected cells are 
believed to be type III latency cells as EBV-specific CTLs are predominantly against 
type III latency antigens in EBV carriers30. If immune system had been suppressed, 
EBV-infected cells (type III latency) may quickly expand as in the case of post-
transplant lymphoproliferative disorder 31,32. We reasoned that xenografts of EBV-
immortalized B lymphocytes (type III latency) into mice could partially mimic the 












overproliferation of EBV-infected cells in vivo during mononucleosis and in a healthy 
EBV-carrier.  
EBV-immortalized B lymphocytes from a SPMS patient (MS-LCL) were 
xenografted into C57BL/6 mice with intraperitoneal injections (i.p.). The age of mice 
was chosen at 4 weeks, which might be similar to human adolescent, a highly 
susceptible period for IM 33. First, we found that C57BL/6 could tolerate 107 MS-LCL 
cells without any apparent effects for a certain period of times. The 107 MS-LCL cells 
were injected into mice every 10-14 days until euthanization (i.p., 5-7 times). No EAE 
symptoms appeared in mice given MS-LCL cells alone (data not shown). Therefore, 
EBV-immortalized cells per se did not induce EAE in C57BL/6 mice under our 
experimental conditions.  
To test whether EBV is a priming factor for MS 34, we xenografted MS-LCL 
into C57BL/6 mice twice, and then the mice were immunized with MOG peptide using 
a standard EAE protocol (Figure 1A) 19. The dosages for MOG peptide were screened 
first and the amounts for minimum EAE inductions were chosen (data not shown). As 
shown in Figure 1B, the MS-LCL inoculation enhanced EAE clinical scores. After 
EAE remission, EBV-infected cells or PBS were administrated into the mice again 
without MOG peptide. In this case MS-LCL alone stimulated an EAE relapse (Figure 
1B; data after Day 29). Therefore, the xenografts of EBV-infected cells could enhance 
the EAE development in a statistically significant manner. 
To verify the enhancement was not a dosage issue, we used a different mouse 
line that is known to be more sensitive to EAE. APP is a protein involved in the 
pathogenesis of brain diseases 35. APP-null mice are more sensitive for EAE inductions 












18. APP-null mice were concurrently used for the same experiments. No statistical 
significant enhancements were observed in APP-null mice administered MS-LCL with 
the same protocol (Figure 1C). The phenotypes of APP-null mice were as previously 
reported: earlier EAE onset, higher clinical scores (compare PBS-treatments between 
APP-null and C57BL/6), and without remission (Figure 1C) 18. The data in APP-null 
mice confirmed that the dosages for EAE inductions were properly selected in the 
C57BL/6 mice.  
Because we have used MS patient-derived EBV-immortalized B lymphocytes, 
it is therefore possible that the MS-specific factor(s) derived from these B cells is 
involved. This possibility is eliminated as EBV-immortalized cells from healthy non-
MS individuals also have similar effects (data not shown). All those data suggest that 
mimicking IM in mice may potentiate EAE development.  
3.2. Challenge with EBV-immortalized cells after EAE remission induces a 
relapse. It is reasonable to assume that the occasional overproliferation of EBV-
positive cells is present in remission stages of MS patients. As EBV-immortalized cells 
might be involved in exacerbating EAE (Figure 1B), we addressed whether there was 
an enhancement in the relapse without prior treatment of EBV-immortalized cells. 
C57BL/6 mice were primed with MS-LCL or PBS prior to initiation of EAE protocol. 
After EAE remission, both groups were challenged with the same MS-LCL cells. As 
seen before, EBV-immortalized MS-LCL caused EAE relapse without further injection 
of MOG peptide. It was apparent that the additional challenge induced a relapse 
(secondary EAE) predominantly in EAE mice primed with MS-LCL (Figure 2A). 
Because of the sample size, we did additional experiments to address whether prior 
exposure to MS-LCL was necessary for a relapse. As shown in Figure 2B, the prior 












MS-LCL treatment was required for the relapse without further MOG treatment. 
Furthermore, we observed that clinical peak scores of the relapses basically aligned 
with the previous clinical scores of the mice induced by MOG peptides.  
To test if the mice had immune responses to EBV-immortalized cells, we 
collected plasmas from several MS-LCL xenografted or PBS-treated mice, and used 
them for Western Blot analysis with identical conditions. The plasmas reacted with 
MS-LCL lysates pretty strongly (data not shown), which indicate that MS-LCL induced 
immune responses against itself. Next whether MS-LCL xenografted mice had a 
specific antibody to EBV latent proteins was examined. Sav I and SavIII are isogenic 
lines with different EBV-latencies: SavI has only one EBV protein expression (type I 
latency), while SavIII has eight or more viral protein expressed (type III latency)4,36,37. 
SavIII and MS-LCL are not the same lines but they have the same EBV latency type. 
As shown in Figure 2C, a MS-LCL xenografted mouse had strong antibody responses 
to EBV-infected human B lymphocytes. Unfortunately, no convincing evidence that 
specific antibodies to EBV latent antigens generated as the EBV-negative ones also 
react with the plasmas. Moreover, different plasmas provided different patterns of 
reactions (data not shown). However, the data in Figure 2C clearly showed that 
xenografted mice had immune response to human B lymphocytes. 
3.3. EBV-immortalized cells elicit changes in gut microbiome associated with EAE 
progression Recent evidence suggests alterations in the gut microbiome of MS patients 
may be a contributor towards the promotion of inflammatory cytokines and overall 
inflammation 38. Moreover, changes in microbiota composition may result in 
imbalances in metabolites produced and nutrients available leading to diseases. As 












such, modulation of the gut microbiome can be viewed as a potential novel therapeutic 
avenue 38-40.  
To evaluate the possible associations between the gut microbiota and EAE 
progression, we performed longitudinal evaluation of the gut microbiota composition as 
described in Figure 1B and Supplemental Table 1. Basically the feces were collected on 
the Day 16, 28, 36, and 50. Ceca were collected on the Day 51 after euthanization. The 
V4 region of the 16S rDNA gene was amplified using barcoded universal primers and 
was multiplexed as previously described41. Resulting amplicons were sequenced using 
a MiSeq Illumina platform with 250-bp paired end sequencing41. The eubacterial 
community of the fecal microbiota was analyzed using Amplicon Sequence Variant 
(ASV) using the Dada2 pipeline 42. Alpha diversity metrics between the two treatment 
groups displayed significant differences in bacterial diversity across time periods (p= 
0.026 – 0.001). Additionally, beta-diversity analysis using weighted-UniFrac 43 
demonstrated significant differences in microbial community compositions between 
PBS and MS-LCL treated mice as a whole (p<0.009) and in a longitudinal manner 
(p<0.001) (Fig 3A). The changes in microbial community were associated with time of 
sampling, including higher abundance of phylum Verrucomicrobia during the initial 
sampling period followed by a decrease in abundance of this taxa over time. 
Additionally, the phyla Firmicutes and Bacteriodetes fluctuated over time (Fig 3B). 
Further analysis of bacterial taxa following the first MS-LCL injection demonstrated an 
increase of Ruminocococceae, and Muribaculaceae families in comparison to PBS 
treated mice. However, different trends were observed with the third MS-LCL 
treatment (D29): an increase of families of Lachinospiraceae and Ruminococaceae, and 
a decrease in Akkermansiaceae family (Fig 3C). Of note that Akkermansiaceae has 












apparent anti-inflammatory functions 44-46. Four female mice (F16-F19, Supplemental 
Table 1) from the same litter were maintained in the same cage. They had received the 
same MS-LCL treatment but presented with different clinical scores that could be 
classified into two groups (Supplemental Figure 1). The differential analysis of 
bacterial taxa between the two phenotypes in this cage displayed differences in taxa 
abundance of Lachinospireceae (Fig 3D). In summary, bacterial community 
composition significantly changed with MS-LCL xenografts.  
3.4. Xenografts of EBV-immortalized cells enhance the integrity of blood brain 
barriers (BBB) in mice The BBB is a highly selective permeability barrier that 
separates circulating blood from the brain’s extracellular fluid in the CNS. Because of 
tight junctions, BBB may prevent the entry of potential neurotoxins. It is generally 
accepted that some cells/factors must cross the BBB and enter the CNS for MS 
pathogenesis 47.  
Because EBV-infected cells were capable of enhancing EAE scores (Figures 1 
and 2), whether those cells could affect BBB permeability before the onset of EAE was 
examined. Mice were xenografted with MS-LCL or PBS, followed by EAE induction. 
Before the onset of EAE (Days 8 and 9), the BBB integrities of the mice were assessed 
with gadolinium (Gd)-enhanced magnetic resonance imaging (MRI). The reason to 
choose MRI over other methods is that MRI can monitor the BBB integrity in a non-
invasive manner. Several areas in the mouse brains were examined systemically, 
including striatum (STR), hippocampus (HP), thalamus (TH), hypothalamus (HY) and 
cerebral cortex (CTX). T1-weighted images were taken prior to and after Gd injection 
and compared. The post-contrast signal intensity in the PBS-control mice might be 
higher than the MS-LCL-injected mice, suggesting that higher Gd deposition in the 












PBS control mice (Figure 4A). Furthermore, T1 values on various areas were measured 
using region-of-interest (ROI) analyses. The T1 shortening in a region suggests the Gd 
entry of brain parenchyma and a strong indicator of comprised BBB integrity 48. Gd-
induced T1-shortening was found in all animals by comparing pre- and post-Gd T1 
values, but was only statistically significant on TH and STR in PBS control mice 
(Figure 4B). The results suggested that the MOG/CFA injection per se could enhance 
BBB disruptions in TH and STR areas. The comparisons of PBS- and MS-LCL-treated 
groups showed that post-Gd T1 values in PBS-treated mice are significantly lower than 
in MS-LCL-treated mice on HY and TH (Figure 4B). The results suggested EBV-
immortalized cells induced tighter BBB integrities in the HY and TH regions under the 
current experimental conditions. This result underscores that extent and regional 
specificity of BBB damage may differ among individual EAE models with different 
methods for detections. 
4. Discussion 
4.1. Potential novel rodent model for human RRMS Approximately 85-90% of 
individuals with MS are initially diagnosed as RRMS. A relapsing-remitting EAE (RR-
EAE) model, representing a course of exacerbations and remissions as occurs in human 
MS, will be extremely useful for both basic research and translational studies. 
Pathophysiological RR-EAE can be induced by passive transfer of the proteolipid 
protein (PLP) reactive cell lines that involve the immunization of donor mice with PLP 
peptides. Additionally, MOG, myelin basic protein (MBP) peptides and MBP reactive 
T cell clones are also used to induce RR-EAE 16,49-51. 












By mimicking behavior of EBV-infected B-lymphocytes in IM in vivo, we 
have shown that xenografts of EBV-immortalized B lymphocytes could induce a 
second EAE response (relapse) (Figures 1, 2). The relapse can be reproducibly 
generated from remitting mice. The unique feature of the system is that severity of the 
relapse can be predicted based on previous clinical scores (Figure 2B). In addition, 
onset time of the relapses can also be predicted. This model might be an additional 
beneficial one for RR-EAE and furthermore RRMS in humans. However, more 
biochemical and pathogenic studies are warranted to verify the current one as a human 
RRMS model. 
4.2. EBV-mediated B cell proliferation in MS development There are several 
possible explanations for the EAE exacerbation by EBV-infected B cells (Figures 1,2). 
One of them is that the EBV-induced proliferation of B lymphocytes or elevated 
presence of B lymphocytes, is a possible factor in MS development. In a healthy 
individual, hyperproliferation of B lymphocytes may be a stress factor for the immune 
system, which is likely to initiate a counteracting response. The process to reduce the 
excessive B lymphocytes may be a trigger for exacerbation of MS. The linkage 
between EBV and MS may be related to the fact that EBV induces overproliferation of 
B cells during primary IM and small but frequent B cell proliferation during 
asymptomatic phase. Of note, MS is associated with deficiencies in EBV-specific 
cytotoxic T lymphocyte (CTL) and uncontrolled lytic replication 13,52,53. CTL 
deficiency would allow the expansion of EBV-infected cells as in immunodeficient 
situations, and higher lytic replication would lead to more EBV virions that promote B 
cells proliferation after primary infection 4. Therefore, both associations may result in a 
hyperproliferation of EBV-infected B cells in vivo. It is noteworthy that clinically 












reductions in B lymphocytes is viewed as a good treatment for MS 54. It is therefore 
tempting to speculate that EBV-mediated B cell proliferation in vivo is a factor in the 
development or exacerbation of MS.  
Our hypothesis about EBV’s role in MS is different from current hypothesized 
ones 13,52, in that it puts the overproliferation of B lymphocytes, rather than EBV per se, 
as a potential risk factor for MS development. Majority of literature support the notion 
that MS is associated with IM. Primary EBV infection may account for 90% of the IM 
cases, and a growing number of pathogens, such as cytomegalovirus, have been 
reported to cause mononucleosis-like illnesses 24,55,56. The literature related IM and MS 
might need re-evaluated with careful etiology of IM examinations. The bacterial 
infection might play an important role in precipitating relapse in MS 57,58. Of note 
bacterial infections may cause B cell proliferation 59. Therefore, our hypothesis about 
EBV, B lymphocytes, and MS may extend to other infectious agents or beyond.  
It is surprising that the challenge of EBV-infected cells actually tightens BBB 
before the onset of EAE (Figure 4). Because preventing BBB untightening is associated 
with reduced EAE in at least SJL mice 60, our study suggests that extent and regional 
specificity of BBB damage differ between individual EAE models and/or at different 
stages.  
Xenografts of EBV-immortalized cells were clearly associated with the 
modulation of the gut microbiome components (Figure 3A). It is possible that gut 
microbiome changes may result in changes in microbial metabolic end products in the 
gut that are associated with EAE61-64. From this limited study, Akkermansiaceae is 
apparently decreased after xenografts, and the supplementation of the bacteria, which is 












apparently safe and effective for other disease 65, might be good for inhibition of 
EAE/MS. 
In summary, our data collectively suggest that overproliferation of EBV-
infected B lymphocytes may be a risk factor for the exacerbation of MS, whereby 
changes are associated with the gut microbiome and BBB. Furthermore, the data herein 
suggest that xenografts of EBV-immortalized cells might be a useful adjunct for RR-
EAE model with a predictable severity and timing in C57BL/6 mice. 
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Figure 1: Exacerbation of EAE in mice xenografted with EBV-immortalized cells. 
A, Mice are injected twice with EBV-immortalized cells (i.p.), then MOG immunization, 
and followed by another injection of EBV-immortalized cells when EAE score is low. 
Drawing is not on scale. B, the 4-week old C57BL/6 mice were first injected (i.p) with 
107 EBV-immortalized SPMS-patient’s B lymphocytes (MS-LCL) (dashed lines; two 
litters, 3 males, 4 females) or PBS (solid lines; two litters, 3 males, 3 females) twice at 
Day -31 and Day -22 respectively. EAE induction was following standard protocol with 
MOG peptide. Mean clinical scores and standard error of the mean (SEM) are shown. 
After the apparent remission of EAE (Day 29, indicated by an arrow), third injection (i.p) 
of MS-LCL (dashed line) or PBS (solid line) respectively was carried out. Mouse feces 
were collected at D16, D28, D36, and D50. At the D51, mice were euthanized and ceca 
were collected for microbiome analyses. At the end of the study, survival rates for all 
groups were 100%. Total 6 out 7 mice with MS-LCL injections, while 2 out 6 PBS-
injected, developed EAE. The detailed information about mice and treatments are 
described in the Supplemental Table 1. Mann-Whitney U one-tailed analysis. *, p≤ 0.05; 
**, p ≤ 0.01. C, APP-null mice (7-week old) were immunized with MS-LCL (dashed 
lines with blue dots; three litters: 3 males, 4 females) or PBS (solid lines with orange 
dots; three litters: 2 males, 3 females). All cells and reagents used were the same, and 
treatments were done simultaneously as in Panel B. At Day 29, third injection of MS-
LCL or PBS respectively was carried out. At the end of the study, total 6 out 7 mice with 
MS-LCL injections, while 5 out 5 mice with PBS-injected, developed EAE. A higher rate 
of mortality was seen in APP-null mice with MS-LCL (3 out 7) compared with PBS 
(death 0 out 5, however one euthanized after reaching EAE score 4). No statistical 
significant differences were noticed between the two groups. 
 












Figure 2: EBV-immortalized cells initiate second EAE response after remission. A, 
C57BL/6 mice were first immunized with MS-LCL as in Figure 1A (dashed lines; one 
litter: 2 males, 2 females) or PBS (solid lines; one litter: 1 male, 2 females) twice. 
MOG-CFA and others were injected as described in the Methods. The severity of EAE 
was scored on daily basis. After the apparent remission of EAE, all mice were injected 
(i.p.) with the same MS-LCL at Day 27, indicated by an arrow. At the end of the study, 
survival rates were 100%. Total 4 out 4 mice with MS-LCL injections, while 2 out 3 
PBS-injected, developed EAE. Mean EAE clinical scores and standard error of the 
mean (SEM) were shown. Student t tests were performed by the use of Microsoft 
Excel. *, p ≤ 0.05; **, p ≤ 0.01. B, C57BL/6 mice were immunized with MS-LCL (two 
litters: 4 males, 4 females) or PBS (two litters: 3 males, 3 females) and followed by 
MOG-CFA injection as in Panel A. At Day 8 and 9, mice were examined by a MRI 
machine. All mice were injected (i.p.) with MS-LCL at remission stage. At the end of 
the study, survival rates were 100%. Total 7 out 8 mice with MS-LCL injections 
(average maximum score: 1.92), while 5 out 6 PBS-injected (average maximum score: 
1.12), developed EAE. The first peak clinical scores were used as a base for calculation 
of the secondary induction efficiency (percentage). Mean secondary induction 
percentages and standard error of the mean (SEM) were shown. Mann-Whitney U one-
tailed analysis. *, p≤ 0.05; C, the plasmas from MS-LCL injected and PBS control mice 
(after three injections) were used for Western Blot analysis as primary antibodies with 
identical conditions. SavIII and MS-LCL are not the same lines but they have the same 
type III EBV latency. Each lane contained approximately the same amounts of proteins 
as determined by ponceau S staining (data not shown), and the protein markers were 
used to facilitate the cutting the membrane into pieces. Each piece was used for 












incubation with one plasma at the same dilutions. They were pieced together for final 
exposure. Molecular weight makers (in kDa) are shown. 
 
  












Figure 3. Gut microbiota community changes in response to Xenografts of EBV-
immortalized cells. Fecal samples were collected as described in Supplemental Table 1 
and the microbial community was analyzed using 16S rDNA sequencing of the V4 
region using the MiSeq Illumina platform. The eubacterial community of the fecal 
microbiota was analyzed using Amplicon Sequence Variant (ASV) using the Dada2 
pipeline. A, Beta-diversity plot showing microbial community differences by treatment 
and time. Colors represent individual mouse identities, shape represents time and size 
of shape represents treatment. The individual identities and treatments are listed in the 
Supplemental Table 1. B, Heatmap showing the relative abundances of the most 
abundant phyla in mice sampled five times. Phylum assignments are shown with 
different colors. The F13-F25 represents the identities of individual mice. The number 
followed represents the dates of the collections. 1=D16, 2=D28, 3=D36, 4=D50, and 
5=D51 (Figure 1B). Treatments are also indicated at the bottom. C, Heatmap of 
differential ASVs identified in each treatment group at the time when differences of 
EAE scores were observed. Collection dates are shown on the top, and the treatments 
are shown at the bottom. Mouse numbers are not shown but can be identified from the 
position: from left to right: F13->F19 in MS-LCL treatments, and F20->F25 in PBS 
controls as in Panel B. D, Differential ASVs are identified in the cage where the four 
mice from the same litter, same sex (F), and same treatment (MS-LCL). The identities 
of the mice are as shown. The F16 and F18 mice had higher EAE clinical scores 
(Supplemental Figure 1). The collection dates are shown on the top.  


























Figure 4: EBV-immortalized cells may tighten the BBB in certain areas of mouse 
brains. A, Mice were treated as described in details in Figure 2B. At Day 8 and 9 after 
MOG-CFA inductions, mice were examined by MRI. No mice had shown any EAE 
signs at the time of examinations. Typical pre- and post-contrast T1-weighted images of 
PBS- and LCL-treated mice are shown. Top row: a PBS-treated mouse, bottom row: a 
MS-LCL-treated mouse. Striatum (STR), hippocampus (HP), thalamus (TH), 
hypothalamus (HY) and cerebral cortex (CTX) arears are indicated. Scale bar: 2 mm. 
B, MRI obtained T1 values on HY, TH, STR, SM, CTX, and HP measured using ROI 
analyses. The T1 shortening on all regions suggests gadolinium entry of brain 
parenchyma. The T1 shortening effect is significant on TH and STR in PBS-treated 
mice. T1 values on HY and TH in PBS-treated mice are significantly lower than in 
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